Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study

By Janssen Paul GH   Gorter Kees J   Stolk Ronald P   Rutten Guy EHM  

British Journal of General Practice, Vol. 59, Iss. 558, 2009-01 ,pp. : 43-48

Royal College of General Practitioners

Access to resources Recommend Favorite

Adherence to guidelines in people with screen-detected type 2 diabetes, ADDITION, Denmark

By Juul Lise   Sandbaek Annelli   Foldspang Anders   Frydenberg Morten   Borch-Johnsen Knut   Lauritzen Torsten  

Scandinavian Journal of Primary Health Care, Vol. 27, Iss. 4, 2009-12 ,pp. : 223-231

Informa Healthcare

Access to resources Recommend Favorite

Testosterone in Men with New and Known Type 2 Diabetes

By  

THE JOURNAL OF SEXUAL MEDICINE, Vol. 12, Iss. 2, 2015-02 ,pp. : 389-397

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen‐detected Type 2 diabetes: analysis of the ADDITION‐UK cluster‐randomized controlled trial

By  

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 907-919

John Wiley & Sons Inc

Access to resources Recommend Favorite

The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) study

By Didangelos T.P.   Thanopoulou A.K.   Bousboulas S.H.   Sambanis C.L.   Athyros V.G.   Spanou E.A.   Dimitriou K.C.   Pappas S.I.   Karamanos B.G.   Karamitsos D.T.  

Current Medical Research and Opinion, Vol. 20, Iss. 9, 2004-09 ,pp. : 1393-1401

Informa Healthcare

Access to resources Recommend Favorite